Early-stage life sciences and healthtech are not just about innovation – they are about belief. Belief that something complex, expensive and uncertain can one day change how we prevent, diagnose, or treat disease.
In the earliest stages, focus is survival. Startups do not lose momentum because competitors move faster – they lose momentum because they try to do too much. Focus on bringing early ideas or prototypes rather than finished products to customers. Failing early, means failing cheaply. AI is disrupting life sciences from optimized in-silico modeling for drug discovery to smarter treatment workflows in clinical settings to mention a few. This means the pressure for speed and focus has never been stronger.
In addition to asking entrepreneurs for focus, customer-centricity, and novelty of thought, capital, too, must evolve. Deep tech in healthcare requires patient money — but even more than that, it requires knowledgeable money. We need more domain experts, clinicians, and operators to become early investors and mentors. In times of geopolitical instability, advising our start-ups on the impact of market drivers like the regulatory shifts in Europe impacting regulatory lead times, understanding how the FDA in the US view wellness vs. medical devices, understanding predictive diagnostics and longevity market drivers, makes a big difference in go-to-market plans. The lessons professionals carry, are as valuable as the capital they invest.
And even if I have certainly learned that breakthrough ideas can fail because the science is weak, they also fail because the ecosystem around them is not designed to carry them forward. Healthcare decision-makers determine whether transformative technologies reach patients or remain promising prototypes. Regulators must continue to experiment as well — especially as AI reshapes diagnostics, treatment pathways, and evidence itself. Scientific progress now moves faster than many of our institutional models were designed to handle. Even our investor models need updating. Calculating risk and return means understanding the new realities our entrepreneurs face.
Even if I am extremely proud of our innovation DNA in Stockholm and Sweden, there are still structural improvements to be made to our fundamental ecosystems. I often reflect on what we could learn in Sweden from approaches like Business Finland — where early-stage deep tech is treated not just as entrepreneurship, but as a national capability. Rather than exclusive soft funding, technology ventures can get these catalyst loans at a much broader scale to accelerate commercialization.
Medicine is becoming more personalized, predictive, and data-driven. However, personalized healthcare requires coordinated systems, investment models, regulatory frameworks, and adoption pathways that are just as adaptive as the science itself.
Innovation is not just discovery. It is delivery. And delivery is something we build together.
“Medicine is becoming more personalized, predictive, and data-driven. However, personalized healthcare requires coordinated systems, investment models, regulatory frameworks, and adoption pathways that are just as adaptive as the science itself.”
